Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Clinuvel Pharmaceuticals Ltd

Healthcare AU CUV

8.93AUD
0.10(1.13%)

Last update at 2026-06-04T06:10:00Z

Day Range

8.809.08
LowHigh

52 Week Range

8.5713.93
LowHigh

Fundamentals

  • Previous Close 8.83
  • Market Cap451.83M
  • Volume55931
  • P/E Ratio14.00
  • Dividend Yield0.56%
  • EBITDA43.68M
  • Revenue TTM96.30M
  • Revenue Per Share TTM1.92
  • Gross Profit TTM 86.32M
  • Diluted EPS TTM0.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 51.55M 50.68M 45.58M 34.32M 25.71M
Minority interest - - - - -
Net income 36.17M 35.64M 30.60M 20.88M 24.73M
Selling general administrative 26.85M 1.74M 22.57M 17.71M 12.76M
Selling and marketing expenses - 23.28M - - -
Gross profit 79.14M 80.45M 69.53M 55.24M 43.26M
Reconciled depreciation 1.18M 1.14M 0.79M 0.76M 0.86M
Ebit 56.02M 55.13M 48.77M 36.60M 27.33M
Ebitda 57.20M 56.28M 49.56M 37.35M 28.19M
Depreciation and amortization 1.18M 1.14M 0.79M 0.76M 0.86M
Non operating income net other - - - - -
Operating income 45.73M 48.01M 44.13M 35.55M 28.57M
Other operating expenses 49.28M 39.03M -18.41361M -11.06945M -12.64121M
Interest expense 4.46M 4.45M 3.19M 2.27M 1.62M
Tax provision 15.38M 15.04M 14.97M 13.44M 0.98M
Interest income 9.43M 7.32M 2.45M 0.44M 0.34M
Net interest income 4.97M 2.87M 0.71M -1.83029M -1.27623M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 15.38M 15.04M 14.97M 13.44M 0.98M
Total revenue 95.02M 88.18M 78.32M 65.72M 47.98M
Total operating expenses 33.40M 31.30M 25.43M 19.91M 15.03M
Cost of revenue 15.88M 7.73M 8.79M 10.48M 4.72M
Total other income expense net 5.82M 2.67M 0.76M 0.82M -1.23556M
Discontinued operations - - - - -
Net income from continuing ops 36.17M 35.64M 30.60M 20.88M 24.73M
Net income applicable to common shares 36.17M 35.64M 30.60M 20.88M 24.73M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 271.75M 231.12M 193.71M 143.95M 108.57M
Intangible assets 0.19M 0.19M - - -
Earning assets - - - - -
Other current assets 2.58M 1.33M 1.07M 1.04M 0.88M
Total liab 30.94M 28.11M 29.08M 18.39M 9.83M
Total stockholder equity 240.81M 203.01M 164.63M 125.56M 98.74M
Deferred long term liab - - - - -
Other current liab 24.23M 22.50M 22.70M 13.47M 4.05M
Common stock 169.28M 168.80M 151.85M 151.85M 151.85M
Capital stock 169.28M 168.80M 151.85M 151.85M 151.85M
Retained earnings 63.63M 29.96M -9.77428M -38.40243M -58.12977M
Other liab - - 2.89M 3.72M 0.08M
Good will - - 0.19M 0.19M 0.19M
Other assets - - 1.06M 0.48M 2.93M
Cash 224.11M 183.87M 156.81M 121.51M 82.69M
Cash and equivalents - - - - -
Total current liabilities 27.21M 25.21M 25.49M 13.73M 8.71M
Current deferred revenue - - -0.30084M -0.31507M 2.07M
Net debt -223.57741M -182.98869M -155.81367M -120.25275M -81.38751M
Short term debt 0.43M 0.37M 0.30M 0.32M 0.26M
Short long term debt - - - - -
Short long term debt total 0.53M 0.88M 1.00M 1.26M 1.30M
Other stockholder equity - - -142.07510M -113.44695M -93.71961M
Property plant equipment - - 2.85M 2.70M 2.60M
Total current assets 262.97M 222.06M 189.62M 140.58M 102.85M
Long term investments 0.21M 0.13M - - -
Net tangible assets - - 164.45M 125.37M 98.55M
Short term investments 196.09M 148.67M 133.93M 98.66M 48.12M
Net receivables 27.46M 26.24M 22.21M 16.20M 16.09M
Long term debt - - - - -
Inventory 8.82M 10.63M 9.52M 1.83M 3.19M
Accounts payable 2.55M 2.35M 2.79M 0.26M 2.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.90M 4.25M 22.56M 12.11M 5.02M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -3.03622M -2.88537M -2.78817M
Deferred long term asset charges - - - - -
Non current assets total 8.78M 9.06M 4.10M 3.37M 5.72M
Capital lease obligations 0.53M 0.88M 1.00M 1.26M 1.30M
Long term debt total - - 0.70M 0.94M 1.05M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -47.71613M -29.03393M -1.02753M -0.43444M -0.85433M
Change to liabilities - - 3.08M 6.06M 0.86M
Total cashflows from investing activities -47.71613M -29.03393M -1.02753M -0.43444M -0.85433M
Net borrowings - - -0.26372M -0.26849M -0.20028M
Total cash from financing activities -2.93863M -3.57181M -2.24013M -1.50376M -1.47995M
Change to operating activities - - -1.41079M -2.53498M -0.02215M
Net income 36.17M 35.64M 30.60M 20.88M 24.73M
Change in cash -7.18010M 3.31M 35.30M 38.82M 15.94M
Begin period cash flow 35.20M 31.89M 121.51M 82.69M 66.75M
End period cash flow 28.02M 35.20M 156.81M 121.51M 82.69M
Total cash from operating activities 41.10M 37.05M 36.91M 39.87M 19.26M
Issuance of capital stock 0.19M 4.16M - - -
Depreciation - 1.14M 0.74M 0.72M 0.82M
Other cashflows from investing activities -47.41757M -23.45771M - - -
Dividends paid -2.50402M -2.47023M -1.97641M -1.23527M -1.23527M
Change to inventory 1.81M -1.10715M -7.68757M 1.35M -1.89876M
Change to account receivables -1.22307M -4.02365M -6.01271M -0.11341M -9.47584M
Sale purchase of stock -0.44091M -4.90925M - - -
Other cashflows from financing activities -0.18270M -0.34734M -0.26372M -0.26849M -0.24469M
Change to netincome - - 8.78M 6.32M 4.25M
Capital expenditures 0.30M 5.58M 1.03M 0.43M 0.85M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.20M -5.06074M -13.70028M 1.24M -11.37460M
Stock based compensation - 6.11M 8.99M 6.12M 2.60M
Other non cash items 38.90M -0.77133M 5.57M 18.28M -6.28577M
Free cash flow 40.80M 31.48M 35.88M 39.44M 18.41M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CUV
Clinuvel Pharmaceuticals Ltd		 0.10 1.13% 8.93 14.00 11.12 4.69 1.81 2.27 4.34
CSL
CSL Ltd		 0.35 0.38% 92.59 11.33 14.35 3.03 1.83 2.86 8.58
TLX
TELIX Pharmaceuticals Ltd		 0.69 5.66% 12.89 - 2500.00 5.49 7.94 4.51 103.05
MSB
Mesoblast Ltd		 - -% 2.02 - 454.55 40.14 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.06 0.44% 13.53 60.00 55.25 27.00 5.17 22.51 66.05

Reports Covered

Stock Research & News

View All

Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Ltd

535 Bourke Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA CEO, MD & Director 1963
Mr. Darren M. Keamy CFO & Company Sec. 1973
Dr. Dennis J. Wright Chief Scientific Officer NA
Mr. Lachlan Hay Director of Global Operations NA
Mr. Malcolm Bull Head of Investor Relations NA
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1963
Mr. Darren Michael Keamy B.Com., CPA CFO & Company Secretary 1973
Mr. Malcolm Bull Head of Australian Operations & Investor Relations NA
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs NA
Dr. Azza Hamila Head of Quality & Drug Safety NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.